Latest News

Latest News

Clinical Trials Roundup | 11 Sept 2026

Clinical Trials Roundup | 11 Sept 2026

Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

read more
The Other Half of Innovation

The Other Half of Innovation

What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

AI-Enabled Pathology: De-risking Oncology Drug Development

AI-Enabled Pathology: De-risking Oncology Drug Development

Today, oncology drug development continues to experience the highest attrition rates across therapeutic areas[1]. Despite major advances in molecular profiling and biomarker-driven strategies, a significant proportion of oncology clinical trials still fail, often due...

read more
Why Sugar May Matter More Than We Thought

Why Sugar May Matter More Than We Thought

A New Energy-Centered Model of Metabolic Disease For decades, sugar has been framed as a problem of excess. Too many calories. Too many insulin spikes. Too much sweetness in the modern diet. That framing has shaped public health guidance, food reformulation, and...

read more
RCM Efficiency: Solving Insurance Denials & Margin Pressure

RCM Efficiency: Solving Insurance Denials & Margin Pressure

Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...

read more
AI-Enabled Pathology: De-risking Oncology Drug Development

AI-Enabled Pathology: De-risking Oncology Drug Development

Today, oncology drug development continues to experience the highest attrition rates across therapeutic areas[1]. Despite major advances in molecular profiling and biomarker-driven strategies, a significant proportion of oncology clinical trials still fail, often due...

read more
Why Sugar May Matter More Than We Thought

Why Sugar May Matter More Than We Thought

A New Energy-Centered Model of Metabolic Disease For decades, sugar has been framed as a problem of excess. Too many calories. Too many insulin spikes. Too much sweetness in the modern diet. That framing has shaped public health guidance, food reformulation, and...

read more
RCM Efficiency: Solving Insurance Denials & Margin Pressure

RCM Efficiency: Solving Insurance Denials & Margin Pressure

Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Innovate UK Awards Over £300k SMART Grant

Innovate UK Awards Over £300k SMART Grant

Funding supports the co-design and roll-out of MEMORI, a Class IIb CE-certified SaMD platform, tailored to local clinical teams and systems MEMORI analyses multimodal clinical data in real-time to accurately predict the risk of hospital-acquired infections, alerting...

read more
Biomanufacturing is the Next Industrial Revolution

Biomanufacturing is the Next Industrial Revolution

Across the life sciences sector, a profound shift is underway. Biomanufacturing is poised to become a foundational pillar of how we will make things in the 21st century. Advances in bioreactor design, synthetic biology, and sustainable bioprocessing are enabling...

read more
Statins Safer Than Previously Thought, Major Review Finds

Statins Safer Than Previously Thought, Major Review Finds

Cholesterol-lowering drugs known as statins, taken by millions worldwide, are significantly safer than often perceived, according to a major new scientific analysis. Conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and published in The Lancet, the...

read more
Emotion-Aware Companion Robotics: Rethinking Aged Care

Emotion-Aware Companion Robotics: Rethinking Aged Care

Ageing at home is widely accepted as the ideal outcome for older adults, families and healthcare systems, but the way we attempt to support it is deeply flawed. Most technologies deployed into homes today are built on a reactive model of care - where they wait for...

read more
Raising Expectations for Medical Liaisons

Raising Expectations for Medical Liaisons

In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...

read more

Further News

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

The Security Blind Spot in Life Science Digitalization

The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...

Making AI Work in a Regulated Medtech Industry

For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...

Measuring the Human Variables Healthcare Systems Continue to Miss

Healthcare organizations have never had more data available to them. Leaders monitor patient satisfaction scores, staffing ratios, productivity, quality indicators, denial rates, wait times, and length of stay. The dashboards are sophisticated, the reporting cadence...

Have We Lost the Plot? Why Life Sciences Can’t Let AI Become the Mission

It’s impossible to escape the topic of AI right now. AI hype in life sciences now dominates every boardroom, industry conference, pitch deck and earnings call. But we’ve seen this movie before. A decade ago, the topic was the cloud, and it, too, was everywhere -...

Biotech IPO 2026: From Drought to Record-Breaking Deals

The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...

Want the FDA to Make Peptides More Accessible?

As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...

The Scientist in the Loop: Why Biopharma R&D Still Needs Human Judgment

Two years into the biopharma industry's most sustained experiment with artificial intelligence, the honest answer to "what has changed" is not the one most conference keynotes suggest. It is not that biopharma AI now runs the laboratory. It is that AI has become very...

How Can We Protect a Failing Heart Using Your Own Mini-Hearts?

Cardiovascular disease in Australia claims one life every 12 minutes. The irreversible damage to the heart is known as heart failure, a condition that progressively prevents the heart from providing the proper amount of blood to our body. This means that patients will...

Early Recognition of Actinic Keratosis in an Aging Population

Healthy aging has changed dramatically over the past several decades. Preventive medicine has expanded well beyond treating disease to identifying health risks before they become serious problems. Today, patients routinely discuss blood pressure, cholesterol,...

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.